1.1Single-chain phosphocholine dispersion
The formulation disperses the phosphocholine in an aqueous vehicle with a nonionic emulsifier. A sealed unit-dose container holds a measured volume for swallowing.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The formulation disperses the phosphocholine in an aqueous vehicle with a nonionic emulsifier. A sealed unit-dose container holds a measured volume for swallowing.
A buffered aqueous vehicle carries dissolved 6-bromotryptophan at the specified concentration. The full 200 ml serving supplies 10 μg, the same mass as 100 ml at 0.1 μg per ml.
Micronized 6-bromotryptophan is dispersed in a molded hard-fat base. The base melts at body temperature and releases the particles to dissolve in rectal fluid.
The syringe contains a sterile, isotonic aqueous solution of 6-bromotryptophan. A short needle deposits a measured volume beneath the skin.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A benchtop swallowing simulator uses an oral liquid containing 0.5 μg/mL of 6-bromotryptophan as a marker for sample recovery. An inlet syringe delivers the liquid onto a flexible tongue surface, and a motor drives the tongue through a programmed compression cycle. An outlet vial collects the transferred liquid, and liquid chromatography measures the recovered marker mass relative to the input mass.
An oral solution uses 6-fluorotryptophan in place of 6-bromotryptophan. A calibrated pipette transfers an aqueous stock of 6-fluorotryptophan into a mixing vessel, and purified water brings the mixture to a final concentration of 0.5 μg/mL. Liquid chromatography against a 6-fluorotryptophan reference solution verifies the concentration before filling.
Two oral liquid presentations contain 2 μg of 6-bromotryptophan per container. The smaller presentation contains 2 mL at 1 μg/mL, and the larger presentation contains 8 mL at 0.25 μg/mL. Separate vessels hold the two dilutions, and a calibrated volumetric filler dispenses each into its designated container.
A collapsible reservoir contains an oral solution with 0.5 μg/mL of 6-bromotryptophan and connects to a positive-displacement pump through a one-way inlet valve. The pump delivers 1 mL per full stroke through a capped dispensing tip into an oral measuring cup. Gravimetric checks use the measured liquid density to convert the mass dispensed per stroke into volume.
A dual-chamber oral package holds 1 mL of a 5 μg/mL 6-bromotryptophan solution in one chamber and 9 mL of purified water in the other. Pressure on the water chamber opens a frangible seal between the chambers. The user inverts the sealed package to mix the contents, then opens the outlet to dispense the resulting 0.5 μg/mL oral solution.
A stock reservoir and a purified-water reservoir feed separate metering pumps connected to a mixing vessel on load cells. A controller uses the assayed stock concentration in μg/g and the target batch mass to calculate the stock mass required for a finished concentration of 0.5 μg/g of 6-bromotryptophan. The controller stops stock addition at the calculated mass, adds water to the target batch mass, and runs an agitator for the programmed mixing interval.
A measured volume of aqueous 6-bromotryptophan concentrate is diluted to a target of 0.20 μg per ml. Liquid chromatography with mass spectrometric detection verifies the concentration in the finished liquid.
A 1 g powder sachet contains 1 μg of 6-bromotryptophan, corresponding to 1 μg per gram. The active ingredient is blended with a small portion of maltodextrin before successive additions of the carrier distribute it through the batch.
Mannitol forms the chewable matrix, and crospovidone promotes breakup on contact with saliva. Chewing fragments the tablet, and the dispersed material is swallowed.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The foregoing needs and other needs and objectives that will become apparent for the following description are achieved in the present invention which comprises the formulation of a rapidly dissolving solid oral dosage form for the delivery of a dietary supplement directed at increasing nitric oxide activity in the body of an individual, e.g. a human or an animal.A · US 7,794,749 B2 · ¶ 8
The oral formulations and methods for use contemplate that the oral formulations are provided in a form suitable for oral administration, e.g., a tablet, a dissolvable tablet, a chewable tablet, a free-flowing powder, a capsule, a gelcap, or incorporated into a food (e.g., biscuit, treat, kibble or gummy).B · US 2017/0340663 A1 · ¶ 35
An empty cell means only that no passage was reproduced there.
It is often desirable to achieve fast release of active compounds of solid oral dosage forms.A · US 7,794,749 B2 · ¶ 3
The invention provides a method for reducing the disintegration time of a solid oral dosage form comprising biologically active ingredients directed at increasing nitric oxide activity.A · US 7,794,749 B2 · ¶ 2
In another aspect, the invention provides a method for supplementing the diet of an animal, such as a human, equine, or other domesticated animal, in need thereof comprising administering to the animal the oral formulations as described and claimed herein.B · US 2017/0340663 A1 · ¶ 4
In a related aspect, the oral formulations for dietary supplementation as described and claimed herein are provided as tablet, a dissolvable tablet, a chewable tablet, a free-flowing powder, a capsule, a gelcap or as part of a foodstuff.B · US 2017/0340663 A1 · ¶ 5
patent.fyi, US 2026/0355158 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355158/, SHA-256 f79eb3653573761ba3a055e06fb2ce9a8618d05da846555adeae22c51c41dcbc